This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
GPR115 Polyclonal Antibody
catalog :
PA5-70825
quantity :
100 uL
price :
US 464.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot
product information
Product Type :
Antibody
Product Name :
GPR115 Polyclonal Antibody
Catalog # :
PA5-70825
Quantity :
100 uL
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Affinity chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
Western Blot: 1.0 ug/mL
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
G protein-coupled receptors (GPCRs, or GPRs) contain 7 transmembrane domains and transduce extracellular signals through heterotrimeric G proteins. GPCR GPR115 is a member of this family (subfamily Orphan-B). ESTs have been isolated from breast, heart, and placenta libraries.
Immunogen :
synthetic peptide directed towards the N-terminal region of human GPR115
Format :
Liquid
Applications w/Dilutions :
Western Blot: 1.0 ug/mL
Aliases :
4632435A09Rik; ADGRF4; Adhesion G protein-coupled receptor F4; AV239010; FLJ38076; G protein-coupled receptor 115; GPR115; G-protein coupled receptor 115; G-protein coupled receptor PGR18; PGR18; probable G-protein coupled receptor 115; RGD1565216; seven transmembrane helix receptor
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments